Updates are available Correction dated 2026-01-27

Article History

Accepted: 4 July 2025

First Online: 27 July 2025

Change Date: 8 January 2026

Change Type: Update

Change Details: In the sentence beginning “At Day 15… in this article, the dose '> 1 mg/day ' corrected as '> 10 mg/day' in PDF version.

Change Date: 27 January 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40263-025-01268-3

Declarations

:

: The study was funded by Lundbeck (Schweiz) AG and coordinated by the contract research organisation, ANFOMED GmbH. The sponsor distributed study documentation to clinicians participating in the study in accordance with the Swiss Pharma Code (Pharmakodex, 2015). The sponsor also reviewed the manuscript for scientific accuracy. All clinicians received an expense allowance for their involvement in the study, which was based on the time required to complete the relevant tasks (communicate information and complete study documentation) at each study visit.

: B.H. is a member of the Swiss Advisory Board on Brintellix, Lundbeck and speaker (Lundbeck-sponsored symposia). G.H. reports speaker/consultant fees from Janssen, Lundbeck, OM Pharma, Salon Pharma, Sanofi, Schwabe, Servier, Sunovion, and Takeda. A.B. is a member of the Swiss Advisory Board on Brintellix, Lundbeck and a speaker in Lundbeck-sponsored symposia. R.B. is a full-time employee of Lundbeck Singapore Pte Ltd. E.R. is a full-time employee of H. Lundbeck A/S. A.S. is a full-time employee of Lundbeck (Schweiz) AG. M.K. holds shares in Roche Pharma AG and Alpine Health AG and received investigator-initiated research funding from Eli Lilly Suisse SA and Pfizer Schweiz AG and speaker honoraria from Eli Lilly Suisse (SA) and Lundbeck AG.

: The datasets analysed during the current study are not publicly available due to reasons of sensitivity but are available from the corresponding author upon reasonable request.

: On 2 April 2017, the Ethics Committee of the Canton of Zurich confirmed that the study protocol did not require specific ethics approval due to its purely observational nature. As treating physicians had decided on treatment independently of the study and prior to inclusion, the study was not considered to fall under the definition of research in humans according to Swiss regulations. With the exception that this study was not registered (owing to its purely observational nature), this study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All patients provided written informed consent prior to enrolment in the study.

: Written informed consent was obtained from all participants included in the study.

: Not applicable.

: Not applicable.

: Conceptualisation: B.H., R.B., A.S. and M.K. Methodology: B.H., R.B., A.S. and M.K. Investigation: A.B. and M.K. Writing – review and editing: B.H., G.H., A.B., R.B., E.R., A.S. and M.K. Supervision: A.S. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.